Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Skye Bioscience, Inc. (SKYE) had Consolidated Net Income/Loss of $-55.92M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-55.92M |
|
-- |
|
-- |
|
$58.16M |
|
$-58.16M |
|
$2.25M |
|
$-55.92M |
|
$-56.28M |
|
$-55.92M |
|
$-55.92M |
|
|
Consolidated Net Income/Loss |
$-55.92M |
$-56.29M |
|
$-58.16M |
|
$-57.44M |
|
39.66M |
|
39.66M |
|
$-1.41 |
|
$-1.41 |
|
| Balance Sheet Financials | |
$27.09M |
|
$0.90M |
|
$1.22M |
|
$28.31M |
|
$8.21M |
|
-- |
|
$0.08M |
|
$8.29M |
|
$20.02M |
|
$20.02M |
|
$20.02M |
|
33.38M |
|
| Cash Flow Statement Financials | |
$-43.06M |
|
$-19.50M |
|
$0.03M |
|
$68.42M |
|
$5.88M |
|
$-62.53M |
|
$7.77M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.30 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-42.71M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-279.29% |
|
-279.29% |
|
-197.52% |
|
-279.29% |
|
$0.60 |
|
$-1.08 |
|
$-1.09 |
|